Bijaya Basyal

Bijaya Basyal

Auto-generated profile, based on publicly available information

Bijaya Basyal

Pokhara University

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2017 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
RPRamesh Sharma Poudel
Ramesh Sharma Poudel
SSShakti Shrestha
Shakti Shrestha
RPRano Mal Piryani
Rano Mal Piryani
BBBijaya Basyal
Bijaya Basyal
KKKalpana Kaucha
Kalpana Kaucha
SAShital Adhikari
Shital Adhikari
Introduction. Proper insulin injection practice is essential for better diabetic control. This study aims to assess the insulin injection practice of patients with diabetes.Materials and Methods. A cross-sectional study was conducted at Chitwan Medical College Teaching Hospital, Bharatpur, Nepal, from February 2017 to May 2017. Patients injecting insulin through insulin pens (n=43) for a minimum of 4 weeks were consecutively recruited. Patients’ baseline characteristics, current insulin injection technique, insulin transportation practice, complications of insulin injection, disposal practice of used needle, and acceptability of insulin were recorded. Descriptive statistics were performed using IBM-SPSS 20.0.Results. The insulin injection technique of patients and their relatives was inadequate. The majority of patients and their relatives (25, 58.1%) mentioned that they transport their insulin cartridge without maintaining cold chain. Thirteen patients (30.2%,n=43) reported complications of insulin injection and the most common complication among those patients was bruising (10, 76.9%,n=13). Almost all patients disposed the used needle improperly, and the common method was disposing the needle in a dustbin and then transferring to municipal waste disposal vehicle. Insulin was accepted by just 16 (37.2%) patients.Conclusion. There was a significant gap between the insulin delivery recommendation through insulin pen and current insulin injection practice.

25 February 2024 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PKPuskar Kunwor
Puskar Kunwor
BBBijaya Basyal
Bijaya Basyal
NPNabin Pathak
Nabin Pathak
PVPankaj Vaidya
Pankaj Vaidya
SSSudip Shrestha
Sudip Shrestha
Introduction: Medication errors (MEs) are preventable incidents that can result in harm to patients. Therefore, it is essential for healthcare professionals (HCPs) to be well-informed about MEs. This study aims to assess the awareness levels of HCPs and the impact of educational intervention on their understanding of MEs. Methods: Responses to a 17-question structured, self-administered questionnaire assessing the awareness of HCPs regarding fundamental aspects of MEs, ME reporting systems, and their ability to make recommendations for improving the system for handling the MEs were collected both before and after two weeks of educational intervention administration. Results: Of a total of 114 HCPs who initially participated in the study, six dropped following the intervention. The awareness regarding the Class A questionnaire was good in most physicians (60%), nurses (60%), and pharmacists (57%) before the intervention, which improved postintervention, with physicians (80%), nurses (32%), and pharmacists (78%) demonstrating excellent awareness. The awareness level in the Class B questionnaire was also improved to excellent in most physicians (70%), pharmacists (85%), and nurses (85%) following the intervention, while it was excellent only in 50%, 35%, and 1% of physicians, pharmacists, and nurses, respectively, preintervention. In the Class C questionnaire, most physicians (40%) and nurses (60%) had good awareness, while pharmacists (35%) demonstrated excellent awareness preintervention. Postintervention, most physicians (70%), nurses (77%), and pharmacists (64%) exhibited excellent awareness. Conclusion: Most oncology practice HCPs demonstrate a good to average level of awareness regarding MEs. Clinical pharmacists’ educational interventions can significantly enhance awareness among HCPs concerning MEs.

6 February 2024 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
SDShreya Dhungana
Shreya Dhungana
NPNabin Pathak
Nabin Pathak
BBBijaya Basyal
Bijaya Basyal
ASAman Kumar Sah
Aman Kumar Sah
APAnjali Pandit
Anjali Pandit
RKRenu Karki
Renu Karki
The role of clinical pharmacists or oncology pharmacists in pediatric oncology has been established as important in anticancer regimen review, dose calculation, recommendation, chemocounseling, identification of drug-related problems, its resolution, and, prevention and monitoring of adverse drug reactions within high-income countries. With several hospitals providing pediatric oncology services in Nepal, clinical pharmacist involvement in these hospitals is very poor. Upon reviewing the reputed organization and association focused on pediatric oncology pharmacy practice, it looks imperative for Nepal to initiate clinical pharmacy services which will further help in improving patient health outcomes. As such in this commentary, we try to accentuate the pediatric oncology services and pediatric pharmacy practice within Nepal and try to pinpoint the potential areas for clinical pharmacists to focus if they intend to provide services in pediatric oncology pharmacy practice.

1 September 2024 in Substance Abuse and Rehabilitation
Verified
Journal Article
Open access
PDF file
NPNabin Pathak
Nabin Pathak
SDShreya Dhungana
Shreya Dhungana
BBBijaya Basyal
Bijaya Basyal
PJPrabhat Kumar Jha
Prabhat Kumar Jha
SSSunil Shrestha
Sunil Shrestha
VPVibhu PAUDYAL
Vibhu PAUDYAL
The unique historical and cultural background of Nepal has shaped its perspective on cannabis usage. Narcotic Drugs Control Act 1976 of Nepal prohibits the cultivation, production, manufacture, sales, and distribution of narcotic drugs, which also include various forms of cannabis. With proponents for cannabis legalization increasing in the country, it is equally crucial to analyze context and practices in countries already adopting legalization. As such, this article contextualizes the current debates in Nepal with global policies and practices and talks about the possible impacts of changing the laws on society, the economy, and public health. Policymakers in Nepal must make decisions based on evidence and facts when deciding how to regulate cannabis.

23 July 2025 in Hospital Pharmacy
Verified
Journal Article
Closed access
NPNabin Pathak
Nabin Pathak
BBBijaya Basyal
Bijaya Basyal
SDShreya Dhungana
Shreya Dhungana
MPMandip Pokharel
Mandip Pokharel
ADAshish Dutta
Ashish Dutta
VPVibhu Paudyal
Vibhu Paudyal

4 April 2026 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
NPNabin Pathak
Nabin Pathak
BBBijaya Basyal
Bijaya Basyal
SDShreya Dhungana
Shreya Dhungana
ASAman Kumar Sah
Aman Kumar Sah
RSRajeev Shrestha
Rajeev Shrestha
RKRenu Karki
Renu Karki
Background: Pediatric patients undergoing chemotherapy often need to take multiple medications. Consequently, they may experience drug-related problems (DRPs), including adverse drug reactions, drug interactions, and various medication errors. Methods: A prospective observational study was conducted over three months in the Pediatric Haemato-oncology department of a cancer specialty hospital of Nepal following ethical approval. DRPs were identified from patient medical records and the literature and, recorded according to the Pharmaceutical Care Network Europe V9.1 tool. Data were collected and analyzed using IBM SPSS Statistics V20 and Microsoft Excel 2013 to present the findings. Results: Among the 30 enrolled patients, 211 DRPs were identified in 28 patients (93.3%), averaging 7.5 DRPs per patient, all validated through case-by-case review. Treatment safety was the predominant DRP type (n = 131; 62.09%), followed by treatment ineffectiveness (n = 79; 37.44%). Drug selection (n = 116; 51.76%) and dispensing issues (n = 51; 22.77%) were the leading causes, with anti-infective drugs (n = 41; 35%) and antineoplastic agents (n = 24; 20.5%) most frequently implicated. Conclusion: DRPs were prevalent among pediatric patients with cancer, with treatment safety being the most significant issue and drug selection being the primary cause. Anti-infective drugs were most frequently involved in DRPs, followed by antineoplastic and immunomodulating agents.